Carolyn Y. Johnson

Now, that the Food and Drug Administration has cleared the first coronavirus vaccine for emergency use in children as young as 12, families are sure to have questions about the Pfizer-BioNTech shot and when it will become available.

Extending vaccine availability to children is considered key to achieving herd immunity, but could set off debates about vaccine mandates in school.

The Novavax coronavirus shot, which relies on a more traditional technology, could be a key tool in the global effort to fight the pandemic.

The findings back up laboratory tests that had suggested the vaccine would protect against variants first identified in South Africa and Britain.

Families and pediatricians have been eager for a vaccine to become available for children, particularly in advance of the next school year.

Making sense of rare, possibly related adverse events after vaccination can be notoriously tricky, but in this case, U.S. health officials have a blueprint.

A massive study unfolding at 20 college campuses aims to determine how well the Moderna coronavirus vaccine prevents vaccinated people from becoming unwitting carriers of the virus.

With three coronavirus vaccines receiving federal clearance, we answer your questions — from when you should get vaccinated to how they work and how they were made so quickly.

The threshold for herd immunity almost certainly won’t be reached without providing vaccines to many of the approximately 75 million people under the age of 18.